

WHO Drug Information

Volume 3, 1989: Index

A

Acetylsalicylic acid, 21, 121
 ADR scheme, UK, 26
 Adverse reaction reporting, 179
 Aerosolized pentamidine, 55
 AIDS therapies update, 19
 vaccines, 122
 a scientific bibliography, 42
 Albendazole, 76
 Alfuzosin, 40
 Allergenic extracts, 69
 Allopurinol, 26
 Almitrine, 13
 American Hospital Formulary, 83
 Aminoglycoside antibiotics, 183
 Amisulpride, 40
 Amoxicillin, 67
 Amphotericin B, 146
 Anabolic steroids, 21
 Anaesthetics/ozone, 63
 Analgesics, renal disease, 59
 Anistreplase, 204
 Antibiotic-resistant pneumococci, 124
 Antibiotics, 165
 in hospitals, 16
 Antileukaemic therapy, 131
 Antimalarials, 174
 for pregnant women, 175
 Antithrombin III, 81
 Antiviral resistance, 61
 Aphrodisiac claims, 183
 Ascariasis, 73
 Asthma management, 181

B

Batroxobin, 204
 Benperidol, 40
 Bioengineering, 131
 Bioequivalence, assurance, 18
 in generics, 20
 Biotechnology, 17
 safety testing, 16
 Bovine brain gangliosides, 137
 British National Formulary Scholarship, 19
 Buprenorphine, 137
 Butyl methoxydibenzoylmethane + padimate O, 81

C

Calcium channel blockers, 173
 Calcium dobesilate, 21
 Capillariasis, 76
 Carbamazepine, 30, 120
 Carcinogenicity prediction, 84

Carfentanil, 25
 Carmofur, 27
 Certification Scheme, certificate, 115
 Cethexonium bromide, 81
 Chloramphenicol, 68, 119
 Chlorofluorocarbons, 138
 Chloroquine, 118
 Ciclosporin, 58, 118
 Cilastatin/imipenem, 67
 Clandestinely produced drugs,
 analogues and precursors, 205
 Clioquinol, bacterial diarrhoea, 9
 Clonidine, 21
 CMEA, 4
 Combination products, 21
 Contact lens cleaning solutions, 26
 Contact lenses, 140
 Contraceptives, progestational (DMPA), 170
 Cosmetic ingredients, 22, 183
 Cost-conscious prescribing, 176
 Cost-effective health care, 176
 Council for Mutual Economic Assistance, 4
 Counterfeit dermatological products, 186
 medicines: IFPMA, 167
 Cromoglicic acid, 182
 Cyclophosphamide, 64
 breast cancer, 11
 gastric cancer, 15

D

Dapsone, 69
 Defective interfering particles, measles vaccine, 65
 Dermatological products, counterfeit, 186
 Diazepam, 32
 Dideoxyinosine, 137
 Dimetindene, 22
 Dipyridamole, HIV, 117
 DMPA, 170
 DNA probes, 180
 Drug administration compliance, 181
 Drug regulation, guiding principles, 43
 Drug-resistant *Staphylococcus aureus*, 14
 Drugs in donated blood, 179
 Drugs used in anaesthesia, 150

E

Encainide, 66
 Encephalitis, Japanese, vaccine, 9
 Enoxaparin, 40
 Enterobiasis, 75
 Epilepsy drugs, 28
 Epoetin alfa, 138
 Erythromycin resistance, 127

Erythropoietin, 40
 recombinant, 138
 Essential Drugs, Model List, 191
 Estrogens and endometrial cancer, 12
 Ethosuximide, 33
 Ethylene oxide, 183
 Exametazime, 40
 Exifone, 138
 Expiry dates, 22
 Exports from Europe, 134

F

Fansidar, counterfeit, 186
 Felodipine, 40
 Fenbufen, 66
 Fenoterol, 57
 Fenticonazole, 40
 Flecainide, 66
 Floctafenine, 69
 Flunarizine, 186
 Fluorouracil, gastric cancer, 15
 breast cancer, 11
 Folate supplements, 128

G

Gamolenic acid, 81
 Ganciclovir, cytomegalovirus retinitis, 13
 GDR restrictive order, 25
 Generic drug products, 178
 Generics legislation in Philippines, 19
 GMP, changes, USA, 125
 shortcomings, 134
 Guiding principles for small national
 drug regulatory authorities, 43

H

Haemophilia therapy, 172
 Haemopoietic growth factors, 172
 Hair restorers, 184
 Hepatitis B vaccine efficacy, 54
 Herbal medicines, hazards, 177
 HIV diagnostic test, 138
 dideoxyinosine, 137
 dipyridamole, 117
 interferon alfa, 117
 HIV-1 antibody fast tests, 13
 Hookworm, 74
 Hormone replacement, 126
 HTLV-1 screening tests, 141
 Hypertension studies, 62
 Hypolipidaemic agents, 135

I

Imipenem/cilastatin, 67
 Immunization, progress, 18
 Immunocytochemical assay for estrogen receptors, 22
 Inactive ingredients disclosure, 63
 Inactive ingredients, 138

Ingredients, inactive, disclosure, 63
 Inspection, pharmaceutical, 206
 Insulins, human, 10
 Interferon alfa, HIV, 117
 Kaposi's sarcoma, 9
 Intestinal infections due to nematodes, 73
 Ipeomide, 81
 Ipriflavone, 81
 Irsogladine maleate, 81
 Isradipine, 82

L

L-Tryptophan, 184
 Labelling errors, 125
 LD₅₀ test, 22
 Legislation, therapeutic goods, 59
 Leishmaniasis, 142
 Leucovorin, breast cancer, 11
 Levamisole, 77
 Lofepamine, 70
 Low osmolar radiocontrast media, 186
 Lysine acetylsalicylate injectables, 70

M

Martindale: 29th edition, 42
 Measles virus yield, 65
 Mebendazole, 77
 Medicines in pregnancy, 149, 175
 Mefloquine, 140, 184
 Meglumine antimoniate, 144
 Metamizole, 185
 Methotrexate, breast cancer, 11
 gastric cancer, 15
 Metronidazole, 23
 Mianserin, 70
 Midazolam, 23
 Minoxidil, 186
 Mitomycin C, gastric cancer, 15
 Model List of Essential Drugs, 191
 Motretinide, 148

N

Naming organic compounds, 205
 Nefopam, 70
 Nematodes, 73
 Nipradilol, 82
 Nizofenone, 148
 Nonsteroidal anti-inflammatories, 23

O

Octenidine, 41
 Oral contraceptives, breast cancer, 53, 130
 genital tract malignancies, 12
 older women, 188
 thromboembolism, 27
 Oral rehydration preparations, 124
 Organic compounds, 205
 Oxidronate disodium + stannous chloride, 82

P

Packaging, child-resistant, 21
Papainases, 27
Pentamidine, 145
 aerosolized, 55
Pentostatin, 23
Pharmaceutical inspection, 206
Pharmacist, role and function in Europe, 205
Pharmacoepidemiology, 59
Phenobarbital, 34
Phenytoin, 36
Pinacidil, 41
Piperazine, 78
Plasma substitutes, 171
Pravastatin, 204
Praziquantel, brand differences, 169
Prednisone, breast cancer, 11
Pregnancy, medicines in, 149, 175
Prenylamine, 23
Prescription, guidelines for children's, 84
Product licensing, administration, 20
Progestational contraceptives (DMPA), 170
Propentofylline, 148
Propofol, 71
Pyrantel, 79
Pyrrolizidine alkaloids, 66, 83

R

Racial differences in drug response, 14
Radiocontrast media, 186
 labelling, 138
 low osmolar, 70
Ramipril, 204
Registration guidelines, India, 24
Registration, Malaysia, 63
Regulation, research and risk of medicines, 83
Resistance, antibiotics, 124, 165
 antivirals, 61
 chloroquine, 118
 erythromycin, 127
 pneumococci, 124
 zidovudine, 117
Retinoids, 187
Rifampicin, 116
Rilmazafone, 204
Role and function of pharmacist in Europe, 205
Rotavirus vaccines, progress, 6

S

Scientific basis of fertility regulation, 149
Sermorelin, 82
Shelf-life and stability, 1
Slimming aids, 67
Sodium stibogluconate, 144
Stability, shelf-life, 1
Steroid aerosols, 187
Steroids, 116
Strongyloidiasis, 74
Sulfamethoxazole/trimethoprim, bloody diarrhoea, 16
Sulfonamide-containing drugs, 25

Sulfonamides, 185
Sulfonylureas, 71
Sulindac, 27
Sultamicillin tosilate, 41
Suxamethonium chloride, 71

T

Tamoxifen, 67
 breast cancer, 11
Tartrazine, 24
Tegafur, 139
Terconazole, 24
Test, HIV, 138
 HTLV-1, 141
 HIV-1 antibodies, 13
Tetracyclines, 72
Theophylline, 24
Therapeutic goods legislation, 59
Thiamazole, 41
Thiamine, 71
Tiabendazole, 80
Tiopronin, 139
Tolrestat, 41
Treatment of terminal breast cancer, 17
Trichostrongyliasis, 75
Trichuriasis, 75
Triptorelin, 24
L-Tryptophan, 184

U

USP Drug Information, 42

V

Vaccine, AIDS, 122
 hepatitis B, efficacy, 54
 Japanese encephalitis, 9
 measles/mumps/rubella, 65
 measles, 65
Valproic acid, 38
Vasodilator therapy, 169
Veterinary drugs, carcinogenicity, 68
Vincristine, gastric cancer, 15
Vitamin injections, 69

W

WFPMM address, 51
WHO Certification Scheme, guidelines, 109

X

Xamoterol, 188

Z

Zidovudine, 117
 carcinogenic potential, 188
Zidovudine-induced neutropenia, 188

